|Bid||111.17 x 100|
|Ask||167.89 x 100|
|Day's Range||130.76 - 132.87|
|52 Week Range||97.52 - 169.89|
|PE Ratio (TTM)||9.24|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It takes just one match to start a fire, but last week the biotech sector got two. Investors should take care not to get burned. The sector got a boost not only from the Senate’s health-care plan, which made nary a mention of the high cost of drugs, but also from a draft of an executive order by President Donald Trump, which appeared to remove the threat of imminent action to rein in prices.
HighCape Partners, a New York equity fund and majority owner of Aziyo, led the funding round for the local company, which creates customized human tissue products for use in orthopedic, spinal, sports medicine and dermal surgeries. Several of its products are allografts — or tissue grafts from donors — for bone repair, ligament replacement and skin grafts.